Britain and America have announced a important bilateral deal that will preserve no levies on UK medicine exports being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the public health system. This pledge guarantees that tariffs on these crucial exports will stay at zero for a timeframe of the next three years.
This deal is in response to recent statements to dramatically increase duties on branded pharmaceutical products, with figures mentioned as high as double the cost.
"This agreement with the Britain strengthens the global environment for cutting-edge drugs and brings much-needed balance to American-British pharmaceutical trade," a statement said.
Trade Impact
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the America, which is easily the primary market for leading British pharmaceutical firms.
Export figures reveal that in the year prior to September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This amount represented 17.4% of British export trade in that timeframe.
"This agreement safeguards jobs, stimulates funding and sets the stage for the UK to become a international leader for life sciences," a government official stated.
Specific UK Commitments
The pact involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to double total public funding on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments topped twenty percent.
Recent Tensions
This agreement comes amid a protracted tension between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
The disagreement were exacerbated by assertions that American customers were paying significantly more for the same drugs than patients in the other developed nations.
Recently, several large manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS must spend more on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the past decade.
